Newsroom 2007
Attention Business/Financial Editors:
Neurochem files shelf prospectus in connection with previously announced equity line of credit facility and convertible notes financings
LAVAL, QC, Jan. 17 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM)
announced today that, in accordance with agreements entered into at the time
of the establishment, in August 2006, of its equity line of credit facility
and the issuance, in November 2006, of US$42.085 million aggregate principal
amount of its 6% senior convertible notes due 2026, it has filed a preliminary
short form base shelf prospectus with the Canadian securities regulators and a
registration statement with the U.S. Securities and Exchange Commission. This
prospectus is in connection with the resale of up to US$60 million of its
common shares which may be issued under the equity line of credit facility, as
well as the resale of such senior convertible notes and of the common shares
issuable upon conversion thereof. An aggregate amount not exceeding
US$102.085 million of securities is being registered under the shelf
prospectus and registration statement.
Neurochem has not been advised by any holder of notes of an intention to
sell the notes or any common shares under the prospectus. In the event that
notes or common shares are to be sold under the shelf prospectus, Neurochem
will prepare and file a prospectus supplement that will include the specific
terms of the designated securities.
When available, copies of the base prospectus and applicable prospectus
supplement may be obtained from Neurochem Inc., Corporate Secretary,
275 Armand-Frappier Boulevard, Laval, Québec, H7V 4A7, or from any underwriter
or dealer participating in the offering.
A registration statement relating to these securities has been filed with
the U.S. Securities and Exchange Commission, but has not yet become effective.
These securities may not be sold, nor may offers to buy be accepted, prior to
the time the registration statement becomes effective. This announcement is
neither an offer to sell nor a solicitation of an offer to buy any of these
securities and shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale is unlawful.
About Neurochem
Neurochem Inc. is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(KIACTA(TM); formerly FIBRILLEX(TM)) is currently being developed for the
treatment of AA amyloidosis, and is under regulatory review for marketing
approval by the U.S. Food and Drug Administration and European Medicines
Agency. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease,
is currently in Phase III clinical trials in both North America and Europe and
tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused
by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks
disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation
and disavows any intention to update or revise such statements as a result of
any event, circumstances or otherwise. Please see the Annual Information Form
for further risk factors that might affect the Company and its business.
For further information: Lise Hébert, PhD, Vice President, Corporate
Communications, (450) 680-4572, Fax: (450) 680-4501, lhebert@neurochem.com
